Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Marketed paracetamol

Phase 3Small molecule

Marketed paracetamol is one of 12 small molecule programs targeting Chickenpox. It is currently in Phase 3.

1

Indications

11

Total Trials

4

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChickenpoxRecruiting

ChickenpoxPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in Chickenpox

#DrugCompanyPhaseTrials

Zovirax

BBp Consulting, Inc

Investigational Cancer Drug

Hepatitis a Vaccine

Vaxneuvance

PCV 20

MMR-Vaccine

Candidate Varicella Vaccine

Marketed paracetamol

YF-Vax

Valtrex

GGlaxo Dba Glaxosmithkline

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Chickenpox

NCT06693895

Q1 2027

Phase 3Recruiting

Chickenpox

NCT06855160

Q2 2027

Phase 3Recruiting

Chickenpox

NCT06806137

Phase 3Recruiting

Chickenpox

NCT06740630

Clinical

Trials by Indication[1]

Chickenpox5 trials

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06693895·750 enrolled

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Completed· GSK logo

GSK·Phase 2·NCT05630846·801 enrolled

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06740630·1,840 enrolled

Show 2 more trials

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06855160·900 enrolled

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06806137·600 enrolled

MPA3 trials

A Study to Compare Two Paracetamol Tablets

Withdrawn· GSK logo

GSK·Phase 1·NCT01381640

A Study to Compare Two Paracetamol Formulations.

Completed· GSK logo

GSK·Phase 1·NCT01592227·30 enrolled

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

Completed· GSK logo

GSK·Phase 1·NCT01476189·28 enrolled

Absorption2 trials

Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®

Completed· GSK logo

GSK·Phase 1·NCT01540734·28 enrolled

Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend

Completed· GSK logo

GSK·Phase 1·NCT01540721·28 enrolled

Scopolamine1 trial

A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.

Completed· GSK logo

GSK·Phase 1·NCT02839135·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Marketed paracetamol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Marketed paracetamol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Marketed paracetamol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Related News